Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thymoglobulin: Phase II; marketed to treat acute rejection of kidney transplants

SANG will begin in the second half of 2003 an

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE